论文部分内容阅读
目的探讨普瑞巴林联合盐酸羟考酮缓释片治疗癌性神经病理痛患者的临床效果。方法选取2013年8月至2015年10月辽宁省本溪市金山医院收治的72例癌性神经病理痛患者作为研究对象,按随机数字表法将其分为观察组和对照组,各36例。对照组患者给予盐酸羟考酮缓释片,观察组患者采用普瑞巴林联合盐酸羟考酮缓释片进行治疗,比较两组患者疼痛情况、生命质量、睡眠质量及不良反应发生情况。结果用药8 d、15 d后,观察组患者的NRS评分、QOL评分、PSQI评分均明显低于对照组,差异均有统计学意义(均P<0.05)。结论采用普瑞巴林联合盐酸羟考酮缓释片治疗癌性神经病理痛患者,可有效减轻患者疼痛程度,提高生命质量,改善睡眠质量,安全性高。
Objective To investigate the clinical effect of pregabalin combined with oxycodone hydrochloride sustained-release tablets in the treatment of patients with malignant neuropathic pain. Methods Seventy-two patients with malignant neuropathic pain admitted from Jinshan Hospital, Benxi City, Liaoning Province from August 2013 to October 2015 were selected as study objects, and divided into observation group and control group according to random number table method, with 36 cases in each group. Patients in the control group were treated with oxycodone hydrochloride sustained-release tablets. The patients in the observation group were treated with pregabalin and oxycodone hydrochloride sustained-release tablets. The pain, quality of life, quality of sleep and adverse reactions were compared between the two groups. Results After treatment for 8 d and 15 d, the scores of NRS, QOL and PSQI in the observation group were significantly lower than those in the control group (all P <0.05). Conclusion The combination of pregabalin and oxycodone hydrochloride sustained-release tablets for the treatment of cancer patients with neuropathic pain can effectively reduce the pain level, improve the quality of life, improve the quality of sleep and have high safety.